Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 68, No. 3, 2009
Issue release date: October 2009
Section title: Original Article
Free Access
Gynecol Obstet Invest 2009;68:167–170

Thiazolidinediones as Therapy for Endometriosis: A Case Series

Moravek M.B.a · Ward E.A.a · Lebovic D.I.a, b
Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology,aUniversity of Michigan, Ann Arbor, Mich. and bUniversity of Wisconsin, Madison, Wisc., USA
email Corresponding Author

Dan Lebovic

University of Wisconsin, Department of Ob/Gyn

Division of Reproductive Endocrinology and Infertility, H4/628 Clinical Science Center

600 Highland Avenue, Madison, WI 53792-3236 (USA)

Tel. +1 734 262 3990, Fax +1 608 262 9862, E-Mail lebovic@wisc.edu


  1. Eskenazi B, Warner ML: Epidemiology of endometriosis. Obstet Gynecol Clin North Am 1997;24:235–258.
  2. D’Hooghe TM, Debrock S, et al: Endometriosis and subfertility: is the relationship resolved? Semin Reprod Med 2003;21:243–254.
  3. Guo SW, Wang Y: The prevalence of endometriosis in women with chronic pelvic pain. Gynecol Obstet Invest 2006;62:121–130.
  4. Petta CA, Ferriani RA, et al: Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod 2005;20:1993–1998.
  5. Treatment of pelvic pain associated with endometriosis. Fertil Steril 2006;86(suppl 5):S18–S27.
  6. Mihalyi A, Simsa P, et al: Emerging drugs in endometriosis. Expert Opin Emerg Drugs 2006;11:503–524.
  7. Surrey ES, Hornstein MD: Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstet Gynecol 2002;99:709–719.
  8. Hughes E, Brown J, et al: Ovulation suppression for endometriosis. Cochrane Database Syst Rev 2007;CD000155.
  9. Pritts EA, Zhao D, et al: PPAR-gamma decreases endometrial stromal cell transcription and translation of RANTES in vitro. J Clin Endocrinol Metab 2002;87:1841–1844.
  10. Ohama Y, Harada T, et al: Peroxisome proliferator-activated receptor-gamma ligand reduced tumor necrosis factor-alpha-induced interleukin-8 production and growth in endometriotic stromal cells. Fertil Steril 2008;89:311–317.
  11. Hornung D, Waite LL, et al: Nuclear peroxisome proliferator-activated receptors alpha and gamma have opposing effects on monocyte chemotaxis in endometriosis. J Clin Endocrinol Metab 2001;86:3108–3114.
  12. Hornung D, Chao VA, et al: Thiazolidinedione inhibition of peritoneal inflammation. Gynecol Obstet Invest 2003;55:20–24.
  13. Giudice LC, Kao LC: Endometriosis. Lancet 2004;364:1789–1799.
  14. Giaginis C, Margeli A, et al: Peroxisome proliferator-activated receptor-gamma ligands as investigational modulators of angiogenesis. Expert Opin Investig Drugs 2007;16:1561–1572.
  15. Lebovic DI, Kir M, et al: Peroxisome proliferator-activated receptor-gamma induces regression of endometrial explants in a rat model of endometriosis. Fertil Steril 2004;82(suppl 3):1008–1013.
  16. Lebovic DI, Mwenda JM, et al: PPAR-gamma receptor ligand induces regression of endometrial explants in baboons: a prospective, randomized, placebo- and drug-controlled study. Fertil Steril 2007;88(suppl 4):1108–1119.
    External Resources
  17. Demirturk F, Aytan H, et al: Effect of peroxisome proliferator-activated receptor-gamma agonist rosiglitazone on the induction of endometriosis in an experimental rat model. J Soc Gynecol Investig 2006;13:58–62.
  18. Biberoglu KO, Behrman SJ: Dosage aspects of danazol therapy in endometriosis: short-term and long-term effectiveness. Am J Obstet Gynecol 1981;139:645–654.
  19. Melzack R: The short-form McGill Pain Questionnaire. Pain 1987;30:191–197.
  20. Nissen SE, Wolsk K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457–2471.
  21. Yaris F, Yaris E, et al: Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman. Reprod Toxicol 2004;18:619–621.
  22. Kalyoncu NI, Yaris F, et al: A case of rosiglitazone exposure in the second trimester of pregnancy. Reprod Toxicol 2005;19:563–564.
  23. Derosa G, Cicero AF, et al: Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial. Clin Ther 2006;28:679–688.
  24. Betteridge DJ: Effects of pioglitazone on lipid and lipoprotein metabolism. Diabetes Obes Metab 2007;9:640–647.
  25. Koninckx PR: Anti-TNF-α treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial. Hum Reprod 2008;9:2017–2023.
    External Resources
  26. Vercellini P, Somigliana E, et al: Endometriosis: current and future medical therapies. Best Pract Res Clin Obstet Gynaecol 2008;22:275–306.